KEY APPROVAL FOR KEPPRA OFFERS NEW TREATMENT OPTION FOR NEWLY DIAGNOSED EPILEPSY PATIENTS

Diagnosed epilepsy patients in Europe with partial onset seizures can now benefit from first-line treatment with Keppra (levetiracetam). This advance in epilepsy management follows the approval of Keppra by the European Commission as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. The new indication is the latest in a series of new indications and formulation approvals, granted to UCB for Keppra this year. Prime Zone (http://www.primezone.com/newsroom/news.html?ref=rss&d=104019)